This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Sep;5(5):339-40.

doi: 10.1007/s11883-003-0003-4.

Losartan reduces cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy

Affiliations

PMID: 12911842
DOI: 10.1007/s11883-003-0003-4

Comment

Losartan reduces cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy

Peter P Toth. Curr Atheroscler Rep. 2003 Sep.

. 2003 Sep;5(5):339-40.

doi: 10.1007/s11883-003-0003-4.

Author

Affiliation

¹ Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA. pptoth@essex1.com

PMID: 12911842
DOI: 10.1007/s11883-003-0003-4

No abstract available

PubMed Disclaimer

Comment on

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.

References

1. Lancet. 2000 Jan 22;355(9200):253-9 - PubMed
1. Lancet. 2002 Mar 23;359(9311):1004-10 - PubMed
1. Lancet. 2002 Mar 23;359(9311):995-1003 - PubMed
1. Arch Intern Med. 1997 Nov 24;157(21):2413-46 - PubMed
1. Lancet. 1999 Feb 20;353(9153):611-6 - PubMed

Publication types

Actions